Reference health
Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin
99/99 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
19 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 99 checked references that resolve
resolves10.1016/j.cllc.2017.10.007
Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non–Small-cell Lung Cancer: Results of a Phase II Study
resolves10.1016/j.addr.2012.09.037
Liposomal drug delivery systems: From concept to clinical applications
resolves10.1016/j.jconrel.2013.07.022
Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38
resolves10.1021/acs.molpharmaceut.5b00785
Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy
resolves10.1056/NEJMoa1814213
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
resolves10.1007/s11095-016-1958-5
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
resolves10.1007/s00280-016-2986-x
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle
resolves10.1158/1078-0432.CCR-16-2401
Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
<i>BRCA1/2</i>
–wild-type Triple-Negative Breast Cancer
resolves10.1016/j.jtho.2017.09.446
MA 01.06 A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Chemotherapy-Resistant Small Cell Lung Cancer
resolves10.1016/j.bmc.2017.04.025
Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects
resolves10.1007/s12094-012-0766-6
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
resolves10.1016/j.carbpol.2018.03.102
New cyclodextrin-based nanocarriers for drug delivery and phototherapy using an irinotecan metabolite
resolves10.1200/jco.2011.29.15_suppl.2598
Population pharmacokinetics of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients with advanced solid tumors.
resolves10.1016/j.jconrel.2016.12.034
Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers
resolves10.2147/IJN.S158426
SN38-loaded &lt;100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study
resolves10.1002/cncr.28358
Randomized phase 2 study of pegylated SN‐38 (EZN‐2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer
resolves10.1007/s00280-010-1303-3
Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial
resolves10.1016/j.jconrel.2010.11.022
G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity
resolves10.18632/oncotarget.4318
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
resolves10.1158/1078-0432.CCR-10-0387
Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors
resolves10.1016/j.gore.2018.05.009
Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
resolves10.1155/2012/262731
Cyclodextrin-Containing Polymers: Versatile Platforms of Drug Delivery Materials
resolves10.1016/j.jconrel.2015.10.031
Amphiphilic drugs as surfactants to fabricate excipient-free stable nanodispersions of hydrophobic drugs for cancer chemotherapy
resolves10.1073/pnas.1106634108
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
resolves10.1126/scitranslmed.aaa5447
Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells
resolves10.1080/1061186X.2017.1419359
Macrophages as an active tumour-targeting carrier of SN38-nanoparticles for cancer therapy
resolves10.1007/s00280-012-1960-5
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors
resolves10.1200/JCO.2004.07.173
Genetic Variants in the <i>UDP-glucuronosyltransferase 1A1</i> Gene Predict the Risk of Severe Neutropenia of Irinotecan
resolves10.1038/sj.tpj.6500072
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
resolves10.1158/1078-0432.CCR-12-1201
A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors
resolves10.1158/0008-5472.CAN-06-1605
Novel SN-38–Incorporating Polymeric Micelles, NK012, Eradicate Vascular Endothelial Growth Factor–Secreting Bulky Tumors
resolves10.1007/s11095-008-9572-9
Potential Oral Delivery of 7-Ethyl-10-Hydroxy-Camptothecin (SN-38) using Poly(amidoamine) Dendrimers
resolves10.1002/jps.23773
Emerging Research and Clinical Development Trends of Liposome and Lipid Nanoparticle Drug Delivery Systems
resolves10.1007/s00280-017-3438-y
Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer
resolves10.1208/s12249-016-0484-4
Preparation, Pharmacokinetic Profile, and Tissue Distribution Studies of a Liposome-Based Formulation of SN-38 Using an UPLC–MS/MS Method
resolves10.1039/C6TB02262F
A multi-stimuli responsive nanoparticulate SN38 prodrug for cancer chemotherapy
resolves10.3109/10717544.2014.895069
Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex:<i>in vitro</i>and<i>in vivo</i>studies
resolves10.1002/adhm.201701140
Functionalized Nanoparticles Efficiently Enhancing the Targeted Delivery, Tumor Penetration, and Anticancer Activity of 7‐Ethyl‐10‐Hydroxycamptothecin
resolves10.1039/C5PY00257E
Hydrogen peroxide-responsive anticancer hyperbranched polymer micelles for enhanced cell apoptosis
resolves10.1002/smll.201000538
Biocompatibility, Biodistribution, and Drug‐Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals
resolves10.1016/j.colsurfb.2016.02.035
Complete regression of xenograft tumors using biodegradable mPEG-PLA-SN38 block copolymer micelles
resolves10.1002/jps.22645
Pharmacokinetics of SN2310, an Injectable Emulsion that Incorporates a New Derivative of SN-38 in Patients with Advanced solid Tumors
resolves10.1016/j.addr.2010.05.008
Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect
resolves10.1080/21691401.2016.1178130
Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy
resolves10.1016/j.ejpb.2016.04.016
Solid lipid nanoparticles containing 7-ethyl-10-hydroxycamptothecin (SN38): Preparation, characterization, in vitro, and in vivo evaluations
resolves10.1007/s11060-015-1795-0
Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma
resolves10.1016/j.jtho.2016.11.1293
P2.03b-012 A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer
resolves10.1021/acs.bioconjchem.7b00774
SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit <i>In Vitro</i> and <i>In Vivo</i> Efficacy
resolves10.1016/j.jtho.2016.09.040
PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer
resolves10.1158/1078-0432.CCR-17-3811
Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model
resolves10.1002/pbc.25105
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors
resolves10.1002/cncr.30789
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
resolves10.1007/s11095-010-0233-4
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
resolves10.1517/17425247.2015.1070142
Challenges in SN38 drug delivery: current success and future directions
resolves10.1016/j.addr.2009.10.003
Targeted delivery of low molecular drugs using chitosan and its derivatives
resolves10.1007/s00280-013-2149-2
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer
resolves10.1155/2013/705265
Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting
resolves10.1016/S1470-2045(15)00332-0
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
resolves10.3324/haematol.2009.008276
Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma
resolves10.1016/j.ijpharm.2014.05.041
MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery
resolves10.1038/s41551-017-0130-9
A non-cytotoxic dendrimer with innate and potent anticancer and anti-metastatic activities
resolves10.1002/smll.201601282
Macrophages as Active Nanocarriers for Targeted Early and Adjuvant Cancer Chemotherapy
resolves10.1158/1078-0432.CCR-14-3321
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
resolves10.1126/science.1183057
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
resolves10.1039/C5RA16175D
Enhanced efficacy of chemotherapeutic drugs against colorectal cancer using ligand-decorated self-breakable agents
resolves10.1208/s12249-013-0068-5
SN-38-Cyclodextrin Complexation and Its Influence on the Solubility, Stability, and In Vitro Anticancer Activity Against Ovarian Cancer
resolves10.1002/adfm.201807446
Assemblies of Peptide‐Cytotoxin Conjugates for Tumor‐Homing Chemotherapy
resolves10.3390/ijerph13121182
Recent Advances on Inorganic Nanoparticle-Based Cancer Therapeutic Agents
resolves10.1016/j.biomaterials.2017.08.002
Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance
resolves10.1002/adma.201300929
Tumor Redox Heterogeneity‐Responsive Prodrug Nanocapsules for Cancer Chemotherapy
resolves10.1021/acsnano.5b02017
The Role of Micelle Size in Tumor Accumulation, Penetration, and Treatment
resolves10.1002/anie.201406685
Structure‐Based Rational Design of Prodrugs To Enable Their Combination with Polymeric Nanoparticle Delivery Platforms for Enhanced Antitumor Efficacy
resolves10.7150/thno.20028
Cancer Nanomedicines Stabilized by π-π Stacking between Heterodimeric Prodrugs Enable Exceptionally High Drug Loading Capacity and Safer Delivery of Drug Combinations
resolves10.1021/acsami.7b01938
Precise Engineering of Prodrug Cocktails into Single Polymeric Nanoparticles for Combination Cancer Therapy: Extended and Sequentially Controllable Drug Release
resolves10.7150/thno.26161
Polylactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma
resolves10.1016/j.actbio.2015.04.021
Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment
resolves10.1080/10717544.2019.1587045
PEGylation of lipophilic SN38 prodrug with DSPE-mPEG<sub>2000</sub> versus cremophor EL: comparative study for intravenous chemotherapy
resolves10.1016/j.jconrel.2012.12.019
Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: In vitro and in vivo studies
resolves10.1002/adma.201000369
Self‐Assembly of Hyperbranched Polymers and Its Biomedical Applications
resolves10.1080/10717544.2016.1177136
Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape
The 19 references without a DOI — listed, not checked
no DOI — not checkedAbstract P6-11-01: significant efficacy in a phase 2 study of NKTR-102, a novel polymer conjugate of Irinotecan, in patients with pre-treated metastatic breast cancer (MBC)
no DOI — not checkedAbstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): results from Phase I/II clinical trial (NCT01631552)
no DOI — not checkedActivity of IMMU-130 anti-CEACAM5-SN-38 antibody-drug conjugate (ADC) on metastatic colorectal cancer (mCRC) having relapsed after CPT-11: phase I study
no DOI — not checkedAbstract CT065: Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results
no DOI — not checkedPhase II study of EZN-2208 (PEG-SN38) with or without cetuximab in patients with metastatic colorectal cancer (CRC)
no DOI — not checkedDimeric drug polymeric micelles with acid-active tumor targeting and FRET-traceable drug release
no DOI — not checkedIntracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
no DOI — not checkedFinal results of a phase I study of liposome encapsulated SN-38 (LE-SN38): safety, pharmacogenomics, pharmacokinetics, and tumor response
no DOI — not checked10.1016/j.ijpharm.2019.118499_b0250
no DOI — not checkedComparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity
no DOI — not checkedClinical pharmacokinetics and metabolism of irinotecan (CPT-11)
no DOI — not checkedLE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: results of CALGB 80402
no DOI — not checkedFinal analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC)
no DOI — not checkedAbstract P3-16-18: phase 2, open-label study of EZN-2208 (PEG-SN38) in patients with previously treated metastatic breast cancer
no DOI — not checked10.1016/j.ijpharm.2019.118499_b0415
no DOI — not checkedPhase II study of NK012 in relapsed small cell lung cancer
no DOI — not checkedAbstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): initial clinical results of two Phase I studies
no DOI — not checkedA phase II study of NK012, a polymeric micelle formulation of SN-38, in colorectal cancer patients who had received prior oxaliplatin-based regimen
no DOI — not checkedSynthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapy
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.ijpharm.2019.118499"><img src="https://citestamp.com/citestamped/10.1016/j.ijpharm.2019.118499/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.ijpharm.2019.118499)